The table below shows the Low Price Pharma Stocks List – Pharma Penny Stocks India based on the Highest Market Capitalization.
Stock | Market Cap (₹ Cr) | Close Price (₹) |
Piramal Pharma Ltd | 29,902.26 | 221.24 |
Marksans Pharma Ltd | 12,368.20 | 267.24 |
Sun Pharma Advanced Research Co Ltd | 5,141.40 | 156.2 |
SeQuent Scientific Ltd | 3,950.76 | 156.58 |
Morepen Laboratories Ltd | 3,355.12 | 58.53 |
Gujarat Themis Biosyn Ltd | 3,142.01 | 274.35 |
Alembic Ltd | 2,897.27 | 111.67 |
Suven Life Sciences Ltd | 2,875.08 | 129.82 |
Indoco Remedies Ltd | 2,584.39 | 265.63 |
Themis Medicare Ltd | 2,137.17 | 220.31 |
Table of Contents
Best Low Price Pharma Stocks
The table below shows the Best Low Price Pharma Stocks based on 1 Year Return.
Stock | Close Price (₹) | 1Y Return (%) |
Bacil Pharma Ltd | 46.93 | 487.36 |
Shukra Pharmaceuticals Ltd | 215.3 | 459.51 |
Venmax Drugs and Pharmaceuticals Ltd | 28.5 | 333.13 |
Desh Rakshak Aushdhalaya Ltd | 25.64 | 268.92 |
Oxygenta Pharmaceutical Ltd | 92.27 | 189.34 |
Gujarat Terce Laboratories Ltd | 79.18 | 178.41 |
Astal Laboratories Ltd | 88.78 | 127.99 |
Tiaan Consumer Ltd | 6.16 | 110.96 |
Welcure Drugs and Pharmaceuticals Ltd | 10.31 | 106.61 |
Jagsonpal Pharmaceuticals Ltd | 242.25 | 98.66 |
Low Price Pharma Stocks Nse
The table below shows Low Price Pharma Stocks Nse based on 1 Month Return.
Stock | Close Price (₹) | 1M Return (%) |
Maitri Enterprises Ltd | 41 | 56.72 |
Sunrest Lifescience Ltd | 62 | 44.39 |
Desh Rakshak Aushdhalaya Ltd | 25.64 | 40.43 |
Venmax Drugs and Pharmaceuticals Ltd | 28.5 | 33.95 |
Ganga Pharmaceuticals Ltd | 17 | 27.72 |
Medico Remedies Ltd | 68.92 | 25.91 |
Shukra Pharmaceuticals Ltd | 215.3 | 23.92 |
Astal Laboratories Ltd | 88.78 | 18.52 |
Norris Medicines Ltd | 21.76 | 18.4 |
Quest Laboratories Ltd | 158.7 | 17.53 |
Low Price Pharma Stocks
The table below shows Pharma Penny Stocks based on the Highest Daily Volume.
Stock | Close Price (₹) | Daily Volume (Cr) |
Murae Organisor Ltd | 1.85 | 16,017,942 |
Morepen Laboratories Ltd | 58.53 | 8,444,012 |
Remedium Lifecare Ltd | 3.93 | 4,446,962 |
Medico Remedies Ltd | 68.92 | 3,885,778 |
Piramal Pharma Ltd | 221.24 | 1,857,059 |
Syncom Formulations (India) Ltd | 18.02 | 1,291,568 |
Johnson Pharmacare Ltd | 1.02 | 1,108,812 |
Alembic Ltd | 111.67 | 827,172 |
Marksans Pharma Ltd | 267.24 | 811,131 |
Nectar Lifesciences Ltd | 35.76 | 651,658 |
Low Price Pharma Stocks India
The table below shows Pharma Penny Stocks India based on the PE Ratio.
Stock | Close Price (₹) | PE Ratio |
Ind Swift Ltd | 15.19 | 1.17 |
IND Swift Laboratories Ltd | 98.14 | 2.07 |
Remedium Lifecare Ltd | 3.93 | 8.09 |
Transchem Ltd | 47 | 10.1 |
Alpa Laboratories Ltd | 112.81 | 10.27 |
Godavari Drugs Ltd | 103.4 | 11.47 |
Tyche Industries Ltd | 150.75 | 11.58 |
Vasundhara Rasayans Ltd | 280 | 14.6 |
Wanbury Ltd | 230 | 16.77 |
Medico Intercontinental Ltd | 42.99 | 17 |
Low Price Pharma Stocks Under 10 Rs
The table below shows Pharma Penny Stocks Under 10 Rs.
Stock | Close Price (₹) | 1Y Return (%) |
Ajooni Biotech Ltd | 7.23 | 21.51 |
Patron Exim Ltd | 7.22 | -19.96 |
EVOQ Remedies Ltd | 7.1 | -46.94 |
Tiaan Consumer Ltd | 6.16 | 110.96 |
Zenith Healthcare Ltd | 5.11 | 20.8 |
Achyut Healthcare Ltd | 4.55 | 13.75 |
Remedium Lifecare Ltd | 3.93 | -82.64 |
Vivanta Industries Ltd | 3.38 | -29.14 |
Cian Healthcare Ltd | 3.34 | -84.52 |
KOBO Biotech Ltd | 2.98 | -40.28 |
Low Price Pharma Stocks List – FAQs
1. Which are the Best Pharma Stocks?
- Best Pharma Stocks #1: Piramal Pharma Ltd
- Best Pharma Stocks #2: Marksans Pharma Ltd
- Best Pharma Stocks #3: Sun Pharma Advanced Research Co Ltd
- Best Pharma Stocks #4: SeQuent Scientific Ltd
- Best Pharma Stocks #5: Morepen Laboratories Ltd
The stocks mentioned are ranked according to their one-year performance.
2. Is it good to invest in Pharma Penny Stocks?
Investing in pharmaceutical penny stocks carries a high risk due to volatility, limited liquidity, and uncertainty. It’s crucial to research thoroughly, consider your risk tolerance, and diversify your portfolio wisely.
3. What are the Low Price NSE Pharma Stocks?
Pharmaceutical stocks encompass companies researching, developing, manufacturing, and distributing drugs and healthcare products. A stock price below 50 Rs may be considered “low-priced” in this sector, but it’s essential to evaluate such stocks based on various factors before investing.
4. What is the future of Pharma Penny Stocks?
The future of Pharma Penny Stocks is uncertain and highly speculative, influenced by regulatory changes, drug developments, and market sentiment. Potential investors should exercise caution and conduct thorough research before investing.
Introduction to Low Price Pharma Stocks List
Low Price Pharma Stocks List – Highest Market Capitalization
Piramal Pharma Ltd
The Market Cap of Piramal Pharma Ltd is ₹29,902.26 crore. The stock’s 1-month return is -5.03%, while its 1-year return is 65.60%. It is currently 93.48% away from its 52-week high.
Piramal Pharma Ltd is a prominent player in the pharmaceutical sector, known for its extensive portfolio that includes contract development and manufacturing (CDMO), critical care, and over-the-counter (OTC) products. The company operates globally, providing end-to-end solutions across the pharmaceutical lifecycle. Piramal Pharma’s CDMO business is a major revenue driver, with a comprehensive suite of services ranging from drug discovery to commercial manufacturing. Their investments in research and development continue to enhance their capabilities, ensuring a pipeline of innovative products.
The company’s strong performance over the past year, reflected in its 65.60% return, highlights its resilience and ability to capitalize on market opportunities. Despite a slight dip of 5.03% in the last month, its long-term growth prospects remain solid. Piramal Pharma continues to explore new markets and strengthen its core segments, which has positioned it favorably for future growth.
Marksans Pharma Ltd
The Market Cap of Marksans Pharma Ltd is ₹12,368.20 crore. The stock’s 1-month return is -0.03%, while its 1-year return is 82.35%. It is currently 105.57% away from its 52-week high.
Marksans Pharma Ltd is engaged in the research, development, manufacturing, and marketing of generic pharmaceutical formulations. The company has a strong presence in regulated markets such as the US, UK, and Australia. Marksans specializes in solid oral dosage forms such as tablets and capsules, with a focus on over-the-counter (OTC) and prescription drugs. Its robust pipeline and strategic acquisitions have contributed significantly to its rapid growth.
The company’s impressive one-year return of 82.35% highlights its strong operational performance. Despite a minor monthly decline of 0.03%, Marksans Pharma remains a strong contender in the pharmaceutical sector. With continued investment in R&D and a focus on expanding its global footprint, the company is poised for sustained long-term growth.
Sun Pharma Advanced Research Co Ltd
The Market Cap of Sun Pharma Advanced Research Co Ltd is ₹5,141.40 crore. The stock’s 1-month return is -15.91%, while its 1-year return is -54.22%. It is currently 1.41% away from its 52-week high.
Sun Pharma Advanced Research Co Ltd (SPARC) is a research-driven pharmaceutical company focused on developing new chemical entities (NCEs) and novel drug delivery systems (NDDS). As a subsidiary of Sun Pharmaceutical Industries, SPARC leverages its parent’s expertise to pursue innovative therapies, particularly in oncology, neurology, and dermatology. The company’s research pipeline has several promising candidates in advanced stages of development.
Despite a sharp one-year decline of -54.22% and a monthly drop of -15.91%, SPARC’s long-term prospects remain promising due to its focus on high-potential therapeutic areas. The company is currently undergoing strategic restructuring to enhance its research efficiency and accelerate the development of key pipeline assets. SPARC’s ability to bring its innovative therapies to market will be crucial in reversing its stock performance and delivering future growth.
Best Low Price Pharma Stocks – 1 Year Return
Bacil Pharma Ltd
The Market Cap of Bacil Pharma Ltd is ₹28.20 crore. The stock’s 1-month return is 3.50%, while its one-year return is 487.36%. It is currently 487.36% away from its 52-week high.
Bacil Pharma Ltd is a pharmaceutical company specializing in generic medications and active pharmaceutical ingredients (APIs). The company has experienced remarkable growth, driven by its ability to capitalize on increasing demand for affordable medications. Bacil Pharma’s commitment to research and innovation enables it to develop cost-effective solutions, catering to a wide range of healthcare needs.
The company’s rapid growth is further supported by its strategic investments in manufacturing capabilities and distribution networks. Despite market fluctuations, Bacil Pharma Ltd’s ability to maintain profitability and expand its market share positions it well for continued success.
Shukra Pharmaceuticals Ltd
The Market Cap of Shukra Pharmaceuticals Ltd is ₹961.80 crore. The stock’s 1-month return is 23.92%, while its one-year return is 459.51%. It is currently 489.22% away from its 52-week high.
Shukra Pharmaceuticals Ltd is a rapidly growing pharmaceutical company known for manufacturing high-quality generic and specialty medications. Their focus on producing affordable medicines has earned them a strong customer base, both domestically and internationally. Shukra Pharmaceuticals continuously invests in state-of-the-art technology to enhance its manufacturing processes and ensure product quality.
The company’s impressive growth has been fueled by strategic partnerships and an expanded product pipeline. With a strong commitment to research and innovation, Shukra Pharmaceuticals Ltd is well-positioned to capitalize on emerging opportunities in the healthcare sector.
Venmax Drugs and Pharmaceuticals Ltd
The Market Cap of Venmax Drugs and Pharmaceuticals Ltd is ₹15.23 crore. The stock’s 1-month return is 33.95%, while its one-year return is 333.13%. It is currently 354.55% away from its 52-week high.
Venmax Drugs and Pharmaceuticals Ltd specializes in producing high-quality pharmaceutical products and APIs. The company’s rapid growth is attributed to its strong manufacturing capabilities and ability to cater to both domestic and international markets. Venmax’s dedication to research and development has resulted in the launch of several innovative products.
The company’s aggressive expansion strategy and ability to form strategic alliances have contributed significantly to its impressive performance. With a focus on enhancing operational efficiencies, Venmax Drugs and Pharmaceuticals Ltd continues to gain momentum in the competitive pharmaceutical industry.
Low Price Pharma Stocks Nse – 1 Month Return
Maitri Enterprises Ltd
The Market Cap of Maitri Enterprises Ltd is ₹17.89 crore. The stock’s 1-month return is 56.72%, while its one-year return is -1.13%. It is currently 75.29% away from its 52-week high.
Maitri Enterprises Ltd operates in the healthcare and pharmaceutical trading sector. The company’s sharp increase in monthly returns is a result of strategic investments and enhanced distribution networks. Maitri Enterprises Ltd has established a reputation for delivering high-quality products and services.
Despite experiencing a slight decline in annual returns, the company remains focused on expanding its market presence and improving operational efficiencies. By continuing to invest in research and technology, Maitri Enterprises Ltd aims to drive sustainable growth in the long term.
Sunrest Lifescience Ltd
The Market Cap of Sunrest Lifescience Ltd is ₹27.64 crore. The stock’s 1-month return is 44.39%, while its one-year return is -12.68%. It is currently 39.01% away from its 52-week high.
Sunrest Lifescience Ltd is a pharmaceutical company specializing in the production of life-saving medications and healthcare products. The company’s ability to quickly respond to market demands has driven its recent surge in monthly returns. Sunrest Lifescience Ltd focuses on expanding its product range through continuous research and development.
Despite facing challenges in annual returns, the company’s strong manufacturing capabilities and efficient distribution network position it well for future growth. Sunrest Lifescience Ltd remains committed to maintaining quality and affordability in its product offerings.
Desh Rakshak Aushdhalaya Ltd
The Market Cap of Desh Rakshak Aushdhalaya Ltd is ₹10.84 crore. The stock’s 1-month return is 40.43%, while its one-year return is 268.92%. It is currently 268.92% away from its 52-week high.
Desh Rakshak Aushdhalaya Ltd is a well-established pharmaceutical company known for producing Ayurvedic and herbal medicines. The company’s impressive stock performance is a result of its consistent efforts to blend traditional remedies with modern scientific research. Desh Rakshak Aushdhalaya Ltd has a strong distribution network that caters to a wide customer base.
The company’s commitment to research and product innovation has driven its growth, enabling it to launch a series of new offerings. With a focus on customer satisfaction and quality assurance, Desh Rakshak Aushdhalaya Ltd is poised for continued success in the healthcare sector.
Pharma Penny Stocks – Highest Day Volume
Murae Organisor Ltd
The Market Cap of Murae Organisor Ltd is ₹164.52 crore. The stock’s 1-month return is -6.84%, while its one-year return is -36.75%. It is currently 77.82% away from its 52-week high.
Murae Organisor Ltd operates in the pharmaceutical and healthcare solutions sector. Despite facing a decline in stock returns, the company remains focused on expanding its service offerings and improving customer experience. Their commitment to quality and affordability has earned them a loyal customer base.
The company is implementing measures to improve operational efficiencies and streamline its supply chain. With continued investment in technology and innovation, Murae Organisor Ltd aims to regain its market momentum and deliver long-term value to shareholders.
Morepen Laboratories Ltd
The Market Cap of Morepen Laboratories Ltd is ₹3,355.12 crore. The stock’s 1-month return is -14.00%, while its one-year return is 19.57%. It is currently 51.83% away from its 52-week high.
Morepen Laboratories Ltd is a well-known pharmaceutical company with a focus on APIs, formulations, and diagnostics. The company has shown resilience in the face of market volatility, driven by its strong manufacturing capabilities and a wide product portfolio. Morepen’s emphasis on R&D and quality standards has strengthened its market presence.
The company continues to invest in expanding its production facilities and developing new products. With a growing customer base and a commitment to innovation, Morepen Laboratories Ltd remains well-positioned to capitalize on future growth opportunities.
Remedium Lifecare Ltd
The Market Cap of Remedium Lifecare Ltd is ₹161.68 crore. The stock’s 1-month return is -33.28%, while its one-year return is -82.64%. It is currently 0.00% away from its 52-week high.
Remedium Lifecare Ltd operates in the pharmaceutical sector, focusing on producing affordable healthcare solutions. Despite recent setbacks in stock performance, the company remains committed to delivering high-quality products. Its recent investments in technology and infrastructure aim to drive future growth.
The company’s challenges are balanced by its long-term growth strategy, which includes expanding into new markets and enhancing operational efficiencies. With a strong focus on innovation, Remedium Lifecare Ltd is poised to regain momentum in the competitive healthcare industry.
Pharma Penny Stocks India – PE Ratio
Ind Swift Ltd
The Market Cap of Ind Swift Ltd is ₹86.01 crore. The stock’s 1-month return is -43.29%, while its one-year return is -22.30%. It is currently 6.22% away from its 52-week high.
Ind Swift Ltd operates in the pharmaceutical sector, specializing in formulations and generic medicines. The company has built a reputation for producing high-quality, affordable medications, catering to both domestic and international markets. Ind Swift Ltd continues to expand its product portfolio and invest in research and development to maintain its competitive edge.
Despite recent market setbacks, the company remains focused on strengthening its distribution channels and improving operational efficiencies. With strategic investments and a strong commitment to innovation, Ind Swift Ltd is well-positioned to navigate challenges and drive long-term growth.
IND Swift Laboratories Ltd
The Market Cap of IND Swift Laboratories Ltd is ₹609.19 crore. The stock’s 1-month return is 0.19%, while its one-year return is -4.58%. It is currently 13.85% away from its 52-week high.
IND Swift Laboratories Ltd is a leading pharmaceutical manufacturing company, known for producing active pharmaceutical ingredients (APIs) and intermediates. The company has invested heavily in research and technology to enhance its production capabilities and maintain a competitive edge in global markets.
With a focus on operational excellence and customer satisfaction, IND Swift Laboratories Ltd is working to expand its market reach and improve profitability. Despite recent performance challenges, the company remains committed to achieving sustainable growth through innovation and market expansion.
Remedium Lifecare Ltd
The Market Cap of Remedium Lifecare Ltd is ₹161.68 crore. The stock’s 1-month return is -33.28%, while its one-year return is -82.64%. It is currently 0.00% away from its 52-week high.
Remedium Lifecare Ltd operates in the pharmaceutical manufacturing and healthcare solutions sector. The company produces a range of pharmaceutical products and healthcare solutions aimed at providing affordable treatments. Recent technological investments aim to drive production efficiency and quality improvements.
Despite significant declines in stock performance, Remedium Lifecare Ltd continues to focus on innovation and operational improvements. The company’s strategy includes expanding into new markets and optimizing its production processes to create long-term value for stakeholders.
Low Price Pharma Stocks Under 10 Rs
Ajooni Biotech Ltd
The Market Cap of Ajooni Biotech Ltd is ₹129.18 crore. The stock’s 1-month return is -5.66%, while its one-year return is 21.51%. It is currently 67.36% away from its 52-week high.
Ajooni Biotech Ltd is a growing player in the biotechnology and animal healthcare segments. The company’s focus on research and sustainable solutions has contributed to steady growth. Ajooni Biotech Ltd continues to expand its product portfolio to meet evolving customer needs.
Despite market fluctuations, the company remains committed to its growth strategy through strategic partnerships and technological advancements. Ajooni Biotech Ltd aims to enhance its market presence and deliver value to stakeholders through innovation.
Patron Exim Ltd
The Market Cap of Patron Exim Ltd is ₹15.90 crore. The stock’s 1-month return is -9.74%, while its one-year return is -19.96%. It is currently 5.25% away from its 52-week high.
Patron Exim Ltd operates within the export and trading sector, specializing in pharmaceutical products. The company has built a reputation for timely deliveries and high-quality products. Its commitment to customer satisfaction has helped maintain a steady client base.
Despite recent declines in stock performance, Patron Exim Ltd is focused on diversifying its product offerings and expanding into new markets. With a strong leadership team and a defined growth strategy, the company is poised to navigate market challenges effectively.
EVOQ Remedies Ltd
The Market Cap of EVOQ Remedies Ltd is ₹17.18 crore. The stock’s 1-month return is -9.80%, while its one-year return is -46.94%. It is currently 7.25% away from its 52-week high.
EVOQ Remedies Ltd is a pharmaceutical company specializing in formulations and APIs. The company is committed to providing affordable healthcare solutions, driving its market presence. EVOQ Remedies Ltd has invested in R&D to enhance its product pipeline.
Although the stock has experienced significant declines, the company remains focused on innovation and operational excellence. With a clear strategy for growth, EVOQ Remedies Ltd aims to improve performance and create long-term value for investors.
We hope you’re clear on the topic, but there’s more to explore in stocks, commodities, mutual funds, and related areas. Here are important topics to learn about.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.